Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Carboxymaltose in Infants with IDA
NCT04968379Phase 2Withdrawn
- Sponsor
- American Regent, Inc.
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by American Regent, Inc. Primary endpoints: Treatment-emergent adverse events, Change in hemoglobin at Day 36 and 5 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04968379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968379.